ID

44238

Descripción

A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH); ODM derived from: https://clinicaltrials.gov/show/NCT01894022

Link

https://clinicaltrials.gov/show/NCT01894022

Palabras clave

Versiones (2)
  1. 15/4/19 15/4/19 -
  2. 20/9/21 20/9/21 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

20 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hypertension NCT01894022

Inglés

Eligibility Hypertension NCT01894022

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
have been randomized to the protocol for amb115811 and have met one of the following: completed the week 16 visit in amb115811; or prematurely withdrew from amb115811 for whatever reason (where investigational product [ip] has been stopped due to safety or efficacy reasons, the subject may still enter into the open label study regardless of what treatment they are receiving [other treatments will not be supplied by the sponsor]. the investigator will decide whether or not the subject will receive the ip
Descripción

Study Subject Participation Status | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
subject is able and willing to give written informed consent. as part of the consent, female subjects of childbearing potential will be informed of the risk of teratogenicity and will need to be counseled in a developmentally appropriate manner on the importance of pregnancy prevention; and male subjects will need to be informed of potential risk of testicular tubular atrophy and aspermia.
Descripción

Informed Consent | Childbearing Potential Information Risk Teratogenesis | Childbearing Potential Information Contraceptive methods | Gender Information Risk Atrophy of testis | Gender Information Risk Aspermia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C1533716
UMLS CUI [2,3]
C0035647
UMLS CUI [2,4]
C0232910
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C1533716
UMLS CUI [3,3]
C0700589
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C1533716
UMLS CUI [4,3]
C0035647
UMLS CUI [4,4]
C0156312
UMLS CUI [5,1]
C0079399
UMLS CUI [5,2]
C1533716
UMLS CUI [5,3]
C0035647
UMLS CUI [5,4]
C1704202
specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the gsk investigational product or other study treatment that may impact subject eligibility is provided in the investigators brochure and product label for pah indication.
Descripción

Information Investigational New Drugs | Information Investigational Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1533716
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C1533716
UMLS CUI [2,2]
C0949266
in france, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
Descripción

Social Security Affiliated | Social Security beneficiary

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0037435
UMLS CUI [1,2]
C1510826
UMLS CUI [2,1]
C0037435
UMLS CUI [2,2]
C1550502
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject meeting any of the following criteria must not receive ambrisentan, however may still be followed-up as part of the study and be treated according to best clinical practice as decided by the investigator:
Descripción

ambrisentan

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1176329
subject has a known hypersensitivity to the investigational products, the metabolites, or formulation excipients
Descripción

Hypersensitivity Investigational New Drugs | Hypersensitivity Metabolite | Hypersensitivity Formulation Excipient

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0870883
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0524527
UMLS CUI [3,3]
C0015237
female subjects who are pregnant or breastfeeding or no-longer agree to comply with using effective contraception as defined in the protocol.
Descripción

Pregnancy | Breast Feeding | Gender Contraceptive methods Refused

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0700589
UMLS CUI [3,3]
C1705116
subjects with alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) >= 3x upper limit of normal (uln)
Descripción

Alanine aminotransferase increased | Aspartate aminotransferase increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
subjects with bilirubin >= 2xuln (>35% direct bilirubin)
Descripción

Elevated total bilirubin | Bilirubin, direct measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0741494
UMLS CUI [2]
C0201916
subjects with severe renal impairment (estimated creatinine clearance <30 millilitre per minute (ml/min) assessed within the previous 45 days) at the point of transition from study amb115811
Descripción

Renal Insufficiency Severe | Estimation of creatinine clearance by Cockcroft-Gault formula

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1565489
UMLS CUI [1,2]
C0205082
UMLS CUI [2]
C2711451
subject has moderate - severe hepatic impairment (child-pugh class b-c with or without cirrhosis) at the point of transition from study amb115811
Descripción

Hepatic impairment Moderate Child-Pugh Classification | Hepatic impairment Severe Child-Pugh Classification | Liver Cirrhosis | Liver Cirrhosis Absent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0948807
UMLS CUI [1,2]
C0205081
UMLS CUI [1,3]
C4050412
UMLS CUI [2,1]
C0948807
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C4050412
UMLS CUI [3]
C0023890
UMLS CUI [4,1]
C0023890
UMLS CUI [4,2]
C0332197
subject with clinically significant fluid retention in the opinion of the investigator
Descripción

Body fluid retention

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0268000
subject with clinically significant anemia in the opinion of the investigator
Descripción

Anemia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0002871
subjects who are to enter another clinical trial or be treated with another investigational product after exiting study amb115811.
Descripción

Study Subject Participation Status | Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
Volver a la parte superior de la página

Similar models

Eligibility Hypertension NCT01894022

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Study Subject Participation Status | Investigational New Drugs
Item
have been randomized to the protocol for amb115811 and have met one of the following: completed the week 16 visit in amb115811; or prematurely withdrew from amb115811 for whatever reason (where investigational product [ip] has been stopped due to safety or efficacy reasons, the subject may still enter into the open label study regardless of what treatment they are receiving [other treatments will not be supplied by the sponsor]. the investigator will decide whether or not the subject will receive the ip
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Informed Consent | Childbearing Potential Information Risk Teratogenesis | Childbearing Potential Information Contraceptive methods | Gender Information Risk Atrophy of testis | Gender Information Risk Aspermia
Item
subject is able and willing to give written informed consent. as part of the consent, female subjects of childbearing potential will be informed of the risk of teratogenicity and will need to be counseled in a developmentally appropriate manner on the importance of pregnancy prevention; and male subjects will need to be informed of potential risk of testicular tubular atrophy and aspermia.
boolean
C0021430 (UMLS CUI [1])
C3831118 (UMLS CUI [2,1])
C1533716 (UMLS CUI [2,2])
C0035647 (UMLS CUI [2,3])
C0232910 (UMLS CUI [2,4])
C3831118 (UMLS CUI [3,1])
C1533716 (UMLS CUI [3,2])
C0700589 (UMLS CUI [3,3])
C0079399 (UMLS CUI [4,1])
C1533716 (UMLS CUI [4,2])
C0035647 (UMLS CUI [4,3])
C0156312 (UMLS CUI [4,4])
C0079399 (UMLS CUI [5,1])
C1533716 (UMLS CUI [5,2])
C0035647 (UMLS CUI [5,3])
C1704202 (UMLS CUI [5,4])
Information Investigational New Drugs | Information Investigational Therapy
Item
specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the gsk investigational product or other study treatment that may impact subject eligibility is provided in the investigators brochure and product label for pah indication.
boolean
C1533716 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C1533716 (UMLS CUI [2,1])
C0949266 (UMLS CUI [2,2])
Social Security Affiliated | Social Security beneficiary
Item
in france, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category
boolean
C0037435 (UMLS CUI [1,1])
C1510826 (UMLS CUI [1,2])
C0037435 (UMLS CUI [2,1])
C1550502 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
ambrisentan
Item
subject meeting any of the following criteria must not receive ambrisentan, however may still be followed-up as part of the study and be treated according to best clinical practice as decided by the investigator:
boolean
C1176329 (UMLS CUI [1])
Hypersensitivity Investigational New Drugs | Hypersensitivity Metabolite | Hypersensitivity Formulation Excipient
Item
subject has a known hypersensitivity to the investigational products, the metabolites, or formulation excipients
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0870883 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0524527 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
Pregnancy | Breast Feeding | Gender Contraceptive methods Refused
Item
female subjects who are pregnant or breastfeeding or no-longer agree to comply with using effective contraception as defined in the protocol.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C1705116 (UMLS CUI [3,3])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
subjects with alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) >= 3x upper limit of normal (uln)
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Elevated total bilirubin | Bilirubin, direct measurement
Item
subjects with bilirubin >= 2xuln (>35% direct bilirubin)
boolean
C0741494 (UMLS CUI [1])
C0201916 (UMLS CUI [2])
Renal Insufficiency Severe | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
subjects with severe renal impairment (estimated creatinine clearance <30 millilitre per minute (ml/min) assessed within the previous 45 days) at the point of transition from study amb115811
boolean
C1565489 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C2711451 (UMLS CUI [2])
Hepatic impairment Moderate Child-Pugh Classification | Hepatic impairment Severe Child-Pugh Classification | Liver Cirrhosis | Liver Cirrhosis Absent
Item
subject has moderate - severe hepatic impairment (child-pugh class b-c with or without cirrhosis) at the point of transition from study amb115811
boolean
C0948807 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C4050412 (UMLS CUI [1,3])
C0948807 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C4050412 (UMLS CUI [2,3])
C0023890 (UMLS CUI [3])
C0023890 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Body fluid retention
Item
subject with clinically significant fluid retention in the opinion of the investigator
boolean
C0268000 (UMLS CUI [1])
Anemia
Item
subject with clinically significant anemia in the opinion of the investigator
boolean
C0002871 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
subjects who are to enter another clinical trial or be treated with another investigational product after exiting study amb115811.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial